James Shayman is professor of internal medicine and pharmacology at the University of Michigan where he holds the Agnes C. And Frank D. McKay Chair in Medicine. He received his medical degree from Washington University and clinical training in medicine and nephrology at Barnes Hospital in St. Louis. Following post-doctoral training in pharmacology he was recruited to Ann Arbor in 1986. His research interests have focused on the pathogenesis and treatment of Gaucher and Fabry diseases. Among his accomplishments are the discovery of eliglustat, the first approved stand-alone substrate reduction agent for Gaucher disease type 1. He has served on several editorial boards and is an inventor on more than sixty US and international patents.